92 related articles for article (PubMed ID: 24295410)
1. Sunitinib in malignant melanoma: a treatment option only for KIT-mutated patients?
Santini D; Vincenzi B; Venditti O; Dell'Aquila E; Frezza AM; Silletta M; Guida FM; Grasso RF; Silvestris N; Lanzetta G; Tonini G
Future Oncol; 2013 Dec; 9(12):1809-11. PubMed ID: 24295410
[TBL] [Abstract][Full Text] [Related]
2. Sunitinib therapy for melanoma patients with KIT mutations.
Minor DR; Kashani-Sabet M; Garrido M; O'Day SJ; Hamid O; Bastian BC
Clin Cancer Res; 2012 Mar; 18(5):1457-63. PubMed ID: 22261812
[TBL] [Abstract][Full Text] [Related]
3. Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.
Buchbinder EI; Sosman JA; Lawrence DP; McDermott DF; Ramaiya NH; Van den Abbeele AD; Linette GP; Giobbie-Hurder A; Hodi FS
Cancer; 2015 Nov; 121(22):4007-15. PubMed ID: 26264378
[TBL] [Abstract][Full Text] [Related]
4. SWITCH: A Randomised, Sequential, Open-label Study to Evaluate the Efficacy and Safety of Sorafenib-sunitinib Versus Sunitinib-sorafenib in the Treatment of Metastatic Renal Cell Cancer.
Eichelberg C; Vervenne WL; De Santis M; Fischer von Weikersthal L; Goebell PJ; Lerchenmüller C; Zimmermann U; Bos MM; Freier W; Schirrmacher-Memmel S; Staehler M; Pahernik S; Los M; Schenck M; Flörcken A; van Arkel C; Hauswald K; Indorf M; Gottstein D; Michel MS
Eur Urol; 2015 Nov; 68(5):837-47. PubMed ID: 25952317
[TBL] [Abstract][Full Text] [Related]
5. [A case of complete response of multiple lung metastases of renal cell carcinoma with the flexible administration of sunitinib].
Kim H; Shoji S; Usui Y; Nagata Y; Terachi T; Uchida T
Hinyokika Kiyo; 2013 Jan; 59(1):7-10. PubMed ID: 23412117
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib-induced nephrotic syndrome in association with drug response in a patient with Xp11.2 translocation renal cell carcinoma.
Liu YC; Chang PM; Liu CY; Yang CY; Chen MH; Pan CC; Chen MH
Jpn J Clin Oncol; 2011 Nov; 41(11):1277-81. PubMed ID: 21965162
[TBL] [Abstract][Full Text] [Related]
7. Pathological activation of KIT in metastatic tumors of acral and mucosal melanomas.
Ashida A; Takata M; Murata H; Kido K; Saida T
Int J Cancer; 2009 Feb; 124(4):862-8. PubMed ID: 19035443
[TBL] [Abstract][Full Text] [Related]
8. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
[TBL] [Abstract][Full Text] [Related]
9. A pilot study of sunitinib malate in patients with metastatic uveal melanoma.
Mahipal A; Tijani L; Chan K; Laudadio M; Mastrangelo MJ; Sato T
Melanoma Res; 2012 Dec; 22(6):440-6. PubMed ID: 23114504
[TBL] [Abstract][Full Text] [Related]
10. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib.
Zimmermann K; Schmittel A; Steiner U; Asemissen AM; Knoedler M; Thiel E; Miller K; Keilholz U
Oncology; 2009; 76(5):350-4. PubMed ID: 19321976
[TBL] [Abstract][Full Text] [Related]
11. Emergence of CTNNB1 mutation at acquired resistance to KIT inhibitor in metastatic melanoma.
Cho J; Kim SY; Kim YJ; Sim MH; Kim ST; Kim NKD; Kim K; Park W; Kim JH; Jang KT; Lee J
Clin Transl Oncol; 2017 Oct; 19(10):1247-1252. PubMed ID: 28421416
[TBL] [Abstract][Full Text] [Related]
12. Long-term response and postsurgical complete remissions after treatment with sunitinib malate, an oral multitargeted receptor tyrosine kinase inhibitor, in patients with metastatic renal cell carcinoma.
Ayllon J; Beuselinck B; Morel A; Barrascout E; Medioni J; Scotte F; Oudard S
Cancer Invest; 2011 May; 29(4):282-5. PubMed ID: 21469976
[TBL] [Abstract][Full Text] [Related]
13. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients.
Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P
Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057
[TBL] [Abstract][Full Text] [Related]
14. Biomarker Analysis in a Phase II Study of Sunitinib in Patients with Advanced Melanoma.
Decoster L; Vande Broek I; Neyns B; Majois F; Baurain JF; Rottey S; Rorive A; Anckaert E; De Mey J; De Brakeleer S; De Grève J
Anticancer Res; 2015 Dec; 35(12):6893-9. PubMed ID: 26637913
[TBL] [Abstract][Full Text] [Related]
15. [Melanoma: from molecular studies to the treatment breakthrough].
Imianitov EN
Arkh Patol; 2013; 75(5):63-72. PubMed ID: 24341237
[TBL] [Abstract][Full Text] [Related]
16. Flare-up: an often unreported phenomenon nevertheless familiar to oncologists prescribing tyrosine kinase inhibitors.
Wolter P; Beuselinck B; Pans S; Schöffski P
Acta Oncol; 2009; 48(4):621-4. PubMed ID: 19107622
[No Abstract] [Full Text] [Related]
17. [Urgent patient admission to Working Group for Urological Oncology (AUO) studies on metastasized renal cell carcinoma needed: prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma ± adjuvant sunitinib therapy over 1 year (SMAT - AN 20/04 of the AUO)].
Rexer H
Urologe A; 2012 Feb; 51(2):252-3. PubMed ID: 22331073
[No Abstract] [Full Text] [Related]
18. Sunitinib for the treatment of metastatic paraganglioma and vasoactive intestinal polypeptide-producing tumor (VIPoma).
Bourcier ME; Vinik AI
Pancreas; 2013 Mar; 42(2):348-52. PubMed ID: 23407483
[TBL] [Abstract][Full Text] [Related]
19. Good response to second-line bevacizumab and interferon-alpha in a sunitinib-refractory patient with metastatic renal cell carcinoma.
Pastorelli D; Zustovich F; Faggioni G; Zovato S; Donach M; Nicoletto O; Farina M; Furini L; Ceravolo R; Carli P; Lombardi G
Anticancer Drugs; 2010 Feb; 21(2):210-3. PubMed ID: 19952729
[TBL] [Abstract][Full Text] [Related]
20. Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.
Vita M; Tisserand JC; Chauvot de Beauchêne I; Panel N; Tchertanov L; Agopian J; Mescam-Mancini L; Fouet B; Fournier B; Dubreuil P; Bertucci F; De Sepulveda P
JAMA Dermatol; 2014 Dec; 150(12):1345-9. PubMed ID: 25317746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]